ACME LaboratoriesDHA:ACMELAB +0.61%82 Gross Margin % is 40.87% as of Mar. 2026, which is 3% above its 10-year median of 39.64. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT125.03 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 936 Drug Manufacturers companies, ACME Laboratories ranks worse than 62.39% on this metric.
The historical rank and industry rank for ACME Laboratories's Gross Margin % or its related term are showing as below:
DHA:ACMELAB'
s Gross Margin % Range Over the Past 10 Years
Min: 38.28 Med: 39.64 Max: 41.51
Current: 41.45
During the past 9 years, the highestGross Margin % of ACME Laboratories was 41.51%. The lowest was 38.28%. And the median was 39.64%.
DHA:ACMELAB's Gross Margin % is ranked worse than 62.39% of 936
companies
in the Drug Manufacturers industry
Industry Median: 48.5
vs DHA:ACMELAB: 41.45
ACME Laboratories had a gross margin of 40.87% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for ACME Laboratories was 1.30% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ACME Laboratories had a gross margin of 40.87% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
ACME Laboratories Gross Margin % Related Terms
ACME Laboratories Gross Margin % Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Gross Margin % distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ACME Laboratories (DHA:ACMELAB) has a Gross Margin % of 40.87% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on ACME Laboratories and its competitors. This is near median its historical median of 39.64. Over the past decade, ACME Laboratories' Gross Margin % has ranged from 38.28 to 41.51. According to the industry distribution chart, ACME Laboratories ranks #584 out of 936 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is ACME Laboratories' Gross Margin % too high?
ACME Laboratories' current Gross Margin % of 40.87% is near median its 10-year median of 39.64. Over the past 10 years, this metric has ranged from a low of 38.28 to a high of 41.51. The Drug Manufacturers industry median Gross Margin % is 48.50. ACME Laboratories' value of 40.87% is 15.7% below this industry median. Based on the distribution chart, ACME Laboratories ranks #584 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #584 out of 936 companies for Gross Margin %. This places ACME Laboratories in the lower half of its industry. The industry median Gross Margin % is 48.50. ACME Laboratories' value of 40.87% is 15.7% below this benchmark. Historically, ACME Laboratories' own Gross Margin % has ranged from 38.28 to 41.51 over the past decade. While the company's 10-year median is 39.64 vs. the industry median of 48.50, ACME Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Gross Margin % of 40.87% is 15.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Gross Margin % is 40.87%, which is near median its own 10-year median of 39.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.03, compared to a current price of BDT82.40 — trading 34.1% below its estimated fair value. The current Gross Margin % is 40.87%, which is near median its 10-year median of 39.64 and 15.7% below the Drug Manufacturers industry median of 48.50. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Gross Margin % is 40.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT82.40 is trading 34.1% below its estimated GF Value™ of BDT125.03.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Gross Margin %: 40.87% (near median its 10-year median of 39.64)
GF Value™: BDT125.03 vs. price of BDT82.40 (34.1% below fair value)
Industry Position: 15.7% below the Drug Manufacturers median (#584 of 936)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score
Get the complete analysis for DHA:ACMELAB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
